Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31
You may also be interested in...
Relenza Originator Aussie Biotech Biota Reports $37 Million In Royalties From GSK
PERTH, Australia - Melbourne-based Relenza developer Biota reported record-breaking royalties of $37.7 million from GlaxoSmithKline for FY2009, almost double the amount it reported a year ago
Relenza Originator Aussie Biotech Biota Reports $37 Million In Royalties From GSK
PERTH, Australia - Melbourne-based Relenza developer Biota reported record-breaking royalties of $37.7 million from GlaxoSmithKline for FY2009, almost double the amount it reported a year ago
Cash-pretty Australian Biotech Biota Returns $20 Million To Shareholders
PERTH, Australia - Just days after unveiling positive results from Phase III trials on its second-generation flu treatment laninamivir, co-developed with Daiichi Sankyo, Aussie Biotech Biota announced Aug. 13 that it would issue AU$20 million to its shareholders